260254-80-6

Basic information

• Product Name: (2S,5R)-1-BENZYL-2,5-DIMETHYLPIPERAZINE
• Synonyms: trans-2R,5S-dimethyl-4-benzyl-piperazine;(2S,5R)-1-BENZYL-2,5-DIMETHYLPIPERAZINE 2HCL;(2S,5R)-Benzyl 2,5-Dimethylpiperazine-1-
• CAS NO: 260254-80-6
• Molecular Formula: C₁₃H₂₀N₂
• Molecular Weight: 204.31
• Mol File: 260254-80-6.mol

Chemical Properties

• Boiling Point: 291.5±20.0 °C(Predicted)
• Appearance: /
• Density: 0.964±0.06 g/cm3(Predicted)
• PKA: 9.35±0.60(Predicted)
• CAS DataBase Reference: (2S,5R)-1-BENZYL-2,5-DIMETHYLPIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,5R)-1-BENZYL-2,5-DIMETHYLPIPERAZINE(260254-80-6)
• EPA Substance Registry System: (2S,5R)-1-BENZYL-2,5-DIMETHYLPIPERAZINE(260254-80-6)

Safety Data

• Hazardous Substances Data: 260254-80-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2S,5R)-1-Benzyl-2,5-dimethylpiperazine is used as a building block for the synthesis of various biologically active compounds. Its structural similarity to other piperazine-based drugs makes it a valuable component in the development of new medications, particularly those aimed at treating neurological disorders and mental health conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (2S,5R)-1-Benzyl-2,5-dimethylpiperazine may have potential applications in the design and synthesis of novel drug candidates. Its unique structure allows for the exploration of its interactions with biological targets, potentially leading to the discovery of new therapeutic agents.
Used in Organic Synthesis:
(2S,5R)-1-Benzyl-2,5-dimethylpiperazine may also find applications in the realm of organic synthesis, where it could serve as a key intermediate in the preparation of complex organic molecules or as a reagent in various chemical reactions, further expanding its utility in the chemical and pharmaceutical industries.

InChI:InChI=1/C13H20N2.2ClH/c1-11-9-15(12(2)8-14-11)10-13-6-4-3-5-7-13;;/h3-7,11-12,14H,8-10H2,1-2H3;2*1H/t11-,12+;;/m1../s1

Upstream product

• 3138-88-3 (+/-)-trans-2,5-dimethyl-4-benzyl-piperazine 
• 3744-87-4 Boc-(R)-Ala 
• 31022-10-3 N-benzyl-L-alanine methyl ester 
• 75-36-5 acetyl chloride 
• 200731-31-3 HATU 
• 100-39-0 benzyl bromide 
• 2815-34-1 2,5-dimethyl-piperazine 
• 3138-88-3 C₁₃H₂₀N₂ 
• 159999-80-1 N-benzyl-N-Boc-L-alanine 
• 1072102-00-1 C₁₄H₂₀N₂O₃*ClH 
• 1072101-99-5 C₁₉H₂₈N₂O₅ 
• 1072102-01-2 (3S,6R)-4-benzyl-3,6-dimethylpiperazine-2,5-dione 
• 431062-00-9 4-benzyl-2R,5S-dimethyl-piperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1046788-31-1 4-(((2R,5S)-4-benzyl-2,5-dimethylpiperazin-1-yl)methyl)tetrahydro-2H-pyran-4-ol 
• 1046788-13-9 (2S,5R)-1-benzyl-2,5-dimethyl-4-(3,3,3-trifluoropropyl)piperazine 
• 1046787-98-7 (2S,5R)-1-benzyl-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazine 
• 1046788-54-8 (2S,5R)-1-benzyl-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-yl)piperazine 
• 1046788-05-9 (2S,5R)-1-benzyl-4-(3-methoxypropyl)-2,5-dimethylpiperazine 

Relevant articles and documents

3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS

The present invention relates to compounds and pharmaceutically acceptable salts of Formulas A and B: (A) and (B) wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disase pression, virus diseases, inflammatory disorders, or diseases in which the liver is a target organ.

3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE C

The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ

Indole-type derivatives as inhibitors of p38 kinase

The invention is directed to methods to inhibit p38-α kinase using compounds comprising a phenyl or thienyl coupled through a piperidine or piperazine nucleus to an indole residue wherein the indole residue mandatorily has a substituent on the ring nitrogen which is an amino or substituted amino group.

Indole-based heterocyclic inhibitors of p38α MAP kinase: Designing a conformationally restricted analogue

p38α Mitogen Activated Protein Kinase (MAP kinase) is an intracellular soluble serine threonine kinase. p38α kinase is activated in response to cellular stresses, growth factors and cytokines such as interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-α). The central role of p38α activation in settings of both chronic and acute inflammation has led efforts to find inhibitors of this enzyme as possible therapies for diseases such as rheumatoid arthritis, where p38α activation is thought to play a causal role. Herein, we report structure-activity relationship studies on a series of indole-based heterocyclic inhibitors that led to the design and identification of a new class of p38α inhibitors.

BENZOFURYLPIPERAZINES AND BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS

The present invention provides serotonergic benzofurylpiperazines of Formula I: where: A is a piperazine of formula: and R, R1, R2, R3, R4, R5, R5', R6, R6', R7, R7', R8, and R8' are as described in the specification.